A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
This research study is looking into a new treatment called BMS-986368 for people who experience muscle stiffness, known as spasticity, due to multiple sclerosis (MS). Many people with MS find spasticity can make everyday tasks difficult. The main goals of this study are to find out if this new medicine is effective at reducing spasticity, if it's safe to use, and how well people cope with taking it. To compare the new medicine, some participants will receive BMS-986368, and others will receive a placebo (a dummy medicine with no active ingredients). This type of study, called a Phase 2 trial, helps researchers learn more about a new treatment before it can be widely used.
En un coup d'œil
De quoi parle cette étude ?
Living with multiple sclerosis (MS) can present many challenges, and one common issue is muscle stiffness, or spasticity. This stiffness can make movements difficult and impact daily life.
Researchers are always looking for new and better ways to manage MS symptoms. This particular study is evaluating a new medicine, BMS-986368, specifically designed to help with spasticity in people with MS. The aim is to see if this medicine can make a real difference for those affected.
During the study, some participants will receive the new medicine, while others will receive a placebo – a substance that looks exactly like the medicine but contains no active ingredients. This is a standard way for researchers to fairly compare the effects of the new medicine. By doing this, they can be sure any changes observed are truly due to the BMS-986368 and not just other factors.
Points clés
- This study evaluates a new drug (BMS-986368) for MS-related muscle stiffness.
- It aims to check the safety, effectiveness, and tolerability of the medicine.
- Some participants will receive the active drug, others a placebo.
- You must have MS and long-standing spasticity to be considered.
- Participation involves clinic visits and close monitoring.
- Vous pouvez arrêter de participer à tout moment.
Qui peut être éligible ?
To be considered for this study, you need to have a diagnosis of multiple sclerosis (MS) and have experienced muscle stiffness (spasticity) related to MS for at least six months. Your muscle stiffness needs to be at a certain level in specific muscle groups, including at least one leg muscle group (but not just your ankle muscles).
There are also some reasons why you might not be able to join. For example, if you have other conditions that cause spasticity or if you've recently had an MS flare-up that required treatment. You also shouldn't have a history of substance abuse or be taking certain medications for spasticity that you can't stop before the study. Specifically, you shouldn't have used any cannabis-related products, including CBD or THC, within 30 days before the study starts. Participants must be between 18 and 70 years old.
Cet étude pourrait-elle vous convenir ?
Répondez à ces questions rapides pour voir si vous êtes éligible. Ceci est un guide uniquement — l'équipe de recherche prend la décision finale.
- Do I have a diagnosis of Multiple Sclerosis (MS)?
- Have I had MS-related muscle stiffness (spasticity) for at least 6 months?
- Is my muscle stiffness present in certain leg muscles (but not just my ankles)?
- Am I between 18 and 70 years old?
- Have I avoided cannabis-related products (like CBD or THC) for at least 30 days?
- Am I not currently taking spasticity medication that I can't stop, or have I not had a recent MS flare-up needing treatment?
En quoi consiste la participation ?
This study involves taking either the new medicine, BMS-986368, or a placebo, which looks identical but has no active ingredients. You would have several visits to the study clinic where various assessments will be done to check how you are doing, including how your spasticity is responding and any side effects you might experience. This will involve physical examinations and other tests. You will be closely monitored by medical staff throughout the study. The total duration of your participation in the study, including all visits and follow-up, will be explained in detail by the study team.
Risques et avantages potentiels
Locations (54)
- Alabama Neurology AssociatesCode postal vérifiéBirmingham, États-Unis· Recrutement
- Perseverance Research Center,LLCCode postal vérifiéScottsdale, États-Unis· Recrutement
- Local Institution - 0017Code postal vérifiéAurora, États-Unis· Retiré
- Aqualane Clinical ResearchCode postal vérifiéNaples, États-Unis· Recrutement
- USF HealthCode postal vérifiéTampa, États-Unis· Recrutement
- University of Kansas Medical CenterCode postal vérifiéKansas City, États-Unis· Recrutement
- Neurology Center of New EnglandCode postal vérifiéFoxborough, United States· Recrutement
- Local Institution - 0071Code postal vérifiéSouthfield, United States· Pas encore en recrutement
- Washington University School of MedicineCode postal vérifiéSaint Louis, États-Unis· Recrutement
- University of Cincinnati Medical CenterCode postal vérifiéCincinnati, United States· Recrutement
- Riverside Methodist HospitalCode postal vérifiéColumbus, États-Unis· Recrutement
- Local Institution - 0069Code postal vérifiéColumbus, États-Unis· Retiré
Questions fréquentes
What is spasticity?
Spasticity is a common symptom of MS that causes your muscles to become stiff, tight, or go into spasms. This can make moving difficult and sometimes painful.
Qu'est-ce qu'un placebo ?
A placebo is a 'dummy' treatment that looks like the real medicine but contains no active ingredients. It helps researchers compare the effects of the new medicine fairly.
What does 'Phase 2' mean for a study?
Phase 2 means this is an early stage of testing where researchers are primarily looking to see if the medicine is safe and if it shows promise in treating the condition, as well as finding the right dose.
Will I know if I'm getting the active medicine or the placebo?
Usually, in this type of study, neither you nor your study doctor will know whether you are receiving the active medicine or the placebo. This is to ensure the results are as unbiased as possible.
Can I continue my other MS treatments if I join?
The study has specific rules about what other medicines you can and cannot take. The study team will review all your current medications to determine if you are eligible.
Comment en savoir plus
Centre de Contact des Essais Cliniques BMS www.BMSClinicalTrials.com
Parlez toujours à votre médecin généraliste ou spécialiste avant de décider de participer à une étude.
Intéressé à participer ?
Discussion
Discussion communautaire
Propulsé par notre forum à community.patient.info. Veuillez être respectueux — ceci n'est pas un avis médical.